ACM
SRPT icon

ADAR1 Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

ADAR1 Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
730,649
+468,591
+179% +$8.86M 0.6% 42
2026
Q1 		$5.7M Buy
262,058
+233,192
+808% +$4.51M 0.34% 69
2025
Q4 		$621K Sell
28,866
-320,941
-92% -$6.76M 0.05% 176
2025
Q3 		$6.74M Buy
349,807
+139,494
+66% +$2.49M 0.63% 41
2025
Q2 		$3.6M Buy
210,313
+87,392
+71% +$3.73M 0.55% 42
2025
Q1 		$7.84M Buy
122,921
+82,919
+207% +$8.73M 1.46% 15
2024
Q4 		$4.86M Buy
40,002
+32,902
+463% +$4.03M 0.97% 26
2024
Q3 		$887K Buy
7,100
+2,650
+60% +$366K 0.14% 86
2024
Q2 		$703K Sell
4,450
-26,655
-86% -$3.42M 0.13% 80
2024
Q1 		$4.03M Buy
31,105
+23,043
+286% +$2.82M 0.91% 19
2023
Q4 		$777K Buy
+8,062
New +$773K 0.28% 50

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

ADAR1 Capital Management's SRPT Position: Q2 2026 in Review

ADAR1 Capital Management increased its Sarepta Therapeutics (SRPT) stake by 179% in Q2 2026, buying an estimated $8.86M and bringing the position to 730,649 shares worth $13.1M. The position accounts for 0.6% of the portfolio, ranked #42.

ADAR1 Capital Management first reported a position in SRPT in Q4 2023 and has held it in 11 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • ADAR1 Capital Management held 730,649 shares of Sarepta Therapeutics worth $13.1M as of Q2 2026.
  • ADAR1 Capital Management bought 468,591 Sarepta Therapeutics shares in Q2 2026, an estimated $8.86M.
  • Sarepta Therapeutics made up 0.6% of ADAR1 Capital Management's portfolio in Q2 2026, its #42 holding.
  • ADAR1 Capital Management first reported a position in Sarepta Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.